Effects of a β-blocker on the cardiovascular response to MDMA (Ecstasy)

Earlier research documents that MDMA (3,4-methylenedioxymethamphetamine, 'Ecstasy') produces marked cardiostimulant effects — notably tachycardia and hypertension — and has been rarely associated with serious vascular events such as myocardial infarction, intracranial haemorrhage and cerebral infarction. In clinical practice, the use of β-adrenergic blockers (β-blockers) in stimulant intoxication is controversial because blockade of β-receptors may, theoretically, remove β 2 -mediated vasodilation and leave unopposed α-receptor vasoconstriction, thereby worsening hypertension or coronary vasospasm. It was unknown whether β-blockers alter the cardiovascular responses to MDMA in humans. M. and colleagues set out to assess the haemodynamic effects of the non-selective β-blocker pindolol on MDMA-induced cardiovascular changes in healthy volunteers. The study aimed to test whether pindolol modifies MDMA-induced increases in heart rate, blood pressure and body temperature, and whether it alters acute adverse effect burden. The cardiovascular and adverse-effect outcomes reported here were secondary outcomes from a controlled human study whose primary subjective and neurocognitive results were reported elsewhere.

The researchers conducted a double-blind, placebo-controlled, single-dose crossover trial with four treatment conditions: placebo→placebo, pindolol→placebo, placebo→MDMA and pindolol→MDMA. Sixteen healthy male volunteers (mean age 25±6 years, range 20–36) completed all four sessions. Sessions were separated by a two-week washout; treatment order was pseudorandomised and counterbalanced so each subject acted as their own control. Pindolol or matching placebo was administered at 09:00, and MDMA or placebo was given 60 minutes later. MDMA hydrochloride was dosed at 1.6 mg/kg (mean 122±14 mg), corresponding to a typical recreational dose, and pindolol was given as a single 20 mg oral dose. Cardiovascular measurements — systolic and diastolic blood pressure, heart rate — and axillary body temperature were recorded at specified times up to 150 minutes after MDMA/placebo (time points corresponding to 60–210 minutes after the initial pindolol/placebo dose). Blood pressure and heart rate were measured once per time point after 5 minutes rest using an ambulatory device. Acute adverse effects were assessed about 75 minutes after MDMA/placebo administration using the 66-item List of Complaints, yielding a total adverse-effects score. Analyses used individual peak effects during the 150-minute post-MDMA window and the area under the curve (AUC) calculated by the trapezoidal rule. One-way repeated measures analysis of variance (ANOVA) with treatment condition as the within-subject factor was applied to peak and AUC values; two-way repeated measures ANOVA (treatment by time) was also used. Post hoc Tukey tests followed significant omnibus effects. Sphericity was assessed and Greenhouse–Geisser corrections applied when necessary. The significance threshold was p<0.05. The authors reported that a sample size of 15 would provide 97% power to detect a 5 mm Hg difference (specifics of this power calculation are stated in the paper).

All 16 subjects completed the four study sessions. Overall, treatment condition produced significant differences in peak heart rate and mean arterial pressure (MAP) across sessions (ANOVA main effects: heart rate F(3,45)=28.7, p<0.001; MAP F(3,45)=47.9, p<0.001). Heart rate: MDMA alone significantly increased peak heart rate compared with placebo by 15±10 beats/min (p<0.01). Peak heart rate values reported were 84±13 beats/min after MDMA versus 69±7 beats/min after pindolol+MDMA. Pindolol pretreatment prevented the MDMA-induced tachycardia (p<0.001 for placebo→MDMA versus pindolol→MDMA). Pindolol given alone did not change heart rate relative to placebo. Blood pressure and MAP: MDMA significantly increased peak MAP by 16±8 mm Hg compared with placebo (p<0.001). Pindolol pretreatment did not alter the MDMA-induced increase in MAP; peak MAP values were similar after MDMA and pindolol+MDMA (115±11 mm Hg vs 114±11 mm Hg as reported). Thus, pindolol blocked the heart rate response but had no detectable effect on MDMA-induced hypertensive responses. Body temperature: MDMA produced a small, non-significant increase in peak body temperature (0.2±0.38°C versus placebo). Pindolol had no effect on MDMA-associated temperature changes. Adverse effects: MDMA significantly increased total acute adverse-effects scores (ANOVA main effect: F(3,45)=10.3, p<0.001). The most frequently reported complaints were impaired balance, lack of appetite, thirst, restlessness or restless legs, difficulty concentrating and thermal discomfort. No subject reported chest pain. Pindolol did not change the adverse-effect profile induced by MDMA.

M. and colleagues interpret their findings to indicate that pindolol, a non-selective β-blocker with intrinsic activity and 5-HT1 receptor antagonism, prevents MDMA-induced tachycardia but does not attenuate MDMA-induced hypertension or the overall acute adverse-effect burden. They note that pindolol had modest effects on certain subjective mood domains in separate analyses (attenuating some positive mood and derealisation effects) but did not affect MDMA-induced cognitive impairment. The authors place their results in the context of stimulant intoxication literature, noting parallels with studies of cocaine in which β-blockade alone may have no effect or may exacerbate hypertension, possibly via unopposed α-receptor stimulation. Their data extend this pattern to MDMA, showing dissociation between heart rate and blood pressure effects under β-blockade. Several limitations are acknowledged. Pindolol is non-selective and has intrinsic sympathomimetic and serotonergic properties; β 1 -selective agents commonly used clinically might interact differently with MDMA. The drug was administered before MDMA to address study aims about 5-HT1 receptor involvement in subjective effects, whereas clinical β-blocker treatment for intoxication would typically be given after ingestion; post-exposure treatment could differ quantitatively. Only single doses of each drug were tested, so dose–response interactions remain unknown. The study used pure MDMA in healthy, resting volunteers; recreational contexts (physical exertion, poly-substance use, comorbidity) may produce different haemodynamic interactions, limiting generalisability to clinical intoxications. The authors also note uncertainty about how the observed haemodynamic changes translate into actual changes in vascular event risk; for example, reduced heart rate and cardiac oxygen consumption might be beneficial despite theoretical risks from unopposed α-stimulation. On the basis of their findings, the authors conclude that β-blockers may mask tachycardia without reducing hypertensive or other adverse effects of MDMA, and therefore recommend further evaluation of combined α–β blockade for MDMA intoxications. They also suggest that because MDMA stimulates sympathetic output centrally rather than peripherally, centrally acting sedatives such as benzodiazepines should remain first-line treatments for stimulant intoxication.